Effects of baru oil supplementation on body composition, inflammation, oxidative stress, lipid profile and blood fatty acids of hemodialysis patients
Not Applicable
- Conditions
- Kidney failure chronic, renal dialysis, inflammation, oxidative stress, dyslipidemias, body composition, fatty acids,C12.777.419.780.750.500C23.550.470G03.673C18.452.584.500E02.870.300G02.111.130D10.251
- Registration Number
- RBR-7trttf
- Lead Sponsor
- niversidade Federal de Goiás
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Chronic renal patients undergoing adequate hemodialysis treatment (Kt / V superior at 1.2), via arteriovenous fistula, of both sexes, aged between 25 and 70 years.
Exclusion Criteria
Patients with a history of acute myocardial infarction in the last six months; recent hospitalization (less than three months from the start of the study), decompensated diabetes, presence of thyroid dysfunction, patients with acute infections and patients who presented food intolerance to baru or allergy to any oilseed.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The present study expects a reduction of 5% in the percentage of body fat (body composition).;The present study is expected to improve inflammation with a 10% reduction in C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) concentrations with a concomitant increase of 10 % on IL-10.;The present study is expected to improve oxidative stress markers with a 10% increase in concentrations of superoxide desmutase (SOD), catalase (CAT) and glutathione peroxidase (GPx).;The present study is expected to improve dyslipidemia with a 10% reduction of LDL-c, total cholesterol and triglycerides with a simultaneous increase of 10% of HDL-c.;The present study is expected to improve the profile of blood fatty acids with a 5% increase in concentrations of polyunsaturated fatty acids and monounsaturated fatty acids with simultaneous decrease of circulating saturated fatty acids.
- Secondary Outcome Measures
Name Time Method With the achievement of the primary outcomes, a reduction of 5% of the cardiovascular risk that these patients are expected is expected.